LENSAR Inc

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

LENSAR Inc (LNSR) reports strong Q1 growth and eyes global expansion

LENSAR Inc (LNSR) delivered robust financial performance in Q1 2024, marked by revenue and procedure growth, expansion of ALLY systems, and market share gains. While facing regulatory challenges and competition, the company's strong financial position and growth opportunities position it well for the future. Continued focus on innovation and market expansion will be key for sustained success.

LENSAR Inc (LNSR) reports robust Q3 earnings, eyes global expansion

LENSAR's Q3 2024 performance reflects strong growth momentum and operational improvements.
While challenges like cost management and market competition persist, the company's strategic strengths position it well for future opportunities.
By capitalizing on its successful international launch and focusing on revenue-driving strategies, LENSAR is poised for continued growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ORLANDO, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted four newly-hired non-executive employees stock options to purchase an aggregate of 2,475 shares of the Company's common stock. The options were granted as of December 8, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer, will participate in a fireside chat at the BTIG 4th Annual Ophthalmology Day on Monday, December 2, 2024 at 2 p.m. ET. Additionally, LENSAR management will host 1-on-1 meetings with institutional investors.

LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day

LENSAR, Inc. (NASDAQ:LNSR ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Good morning, and thank you for participation. At this time, all participants are in a listen-only mode.

LENSAR, Inc. (LNSR) Q3 2024 Earnings Call Transcript

24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024

LENSAR Reports Third Quarter 2024 Results and Provides Business Update

ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, November 7, 2024 to discuss the financial results and recent corporate highlights.

LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

ORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that more than one million procedures have been performed using its technology.

One Millionth Procedure Completed Using LENSAR's Cataract Laser Systems

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that management will participate in two upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment Conference On-demand presentation available Monday, September 9, 2024 at 7:00 a.m. Eastern Time. Lake Street Capital Markets 8th Annual Best Ideas Growth Conference Managem.

LENSAR to Participate in Two Upcoming Investor Conferences

LENSAR, Inc. (NASDAQ:LNSR ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Cameron Radinovic - IR Nicholas Curtis - CEO & Director Thomas Staab - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ryan Zimmerman - BTIG Operator Good morning and thank you for your participation. [Operator Instructions].

LENSAR, Inc. (LNSR) Q2 2024 Earnings Call Transcript

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2024 and provided an update on key operational initiatives. “The second quarter was yet another period of solid growth driven by a record number of 17 ALLY® System placements, a substantive increase in our backlog of ALLY Systems pending in.

LENSAR Reports Second Quarter 2024 Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the ALLY Adaptive Cataract Treatment System (“ALLY” or “ALLY System”) has received certification under the European Union's (“EU”) Medical Device Regulation (“MDR”). “We are thrilled to receive EU MDR certification for ALLY, which marks a significant milestone for LENSAR. We believe A.

LENSAR Announces Certification for the ALLY® Adaptive Cataract Treatment System in the European Union

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the Company's second quarter 2024 financial results will be released before market open on Thursday, August 8, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, August 8, 2024 to discuss the financial results and recent corporate highlights.

LENSAR to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Cadiz

PaySign Inc

Buying low-priced stocks with explosive potential is any investor's dream — but it's not easy. Many stocks trade under $10 in the market, yet not all are quality picks.

3 Under-$10 Stocks With the Potential to Make You a Millionaire

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 1:40 p.m. CT in Austin, TX. The live and archived webcast can be accessed through the Investors section of.

LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference

LENSAR, Inc. (NASDAQ:LNSR ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nicholas Curtis - CEO Thomas Staab - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ryan Zimmerman - BTIG Operator Good morning, and thank you for your participation. At this time, all participants are in a listen-only mode.

LENSAR, Inc. (LNSR) Q1 2024 Earnings Call Transcript

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives. “Recognition of ALLY's advantages, its ability to achieve higher efficiencies for surgeons and staff as well as better surgical outcomes for patients, allowed us to del.

LENSAR Reports First Quarter 2024 Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, May 9, 2024 to discuss the financial results and recent corporate highlig.

LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

LENSAR, Inc. (NASDAQ:LNSR ) Q4 2023 Earnings Conference Call March 4, 2024 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Operator Good morning and thank you for your participation. At this time all participants are in a listen-only mode.

LENSAR, Inc. (LNSR) Q4 2023 Earnings Call Transcript

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2023 and provided an update on key operational initiatives. “Our strong performance throughout 2023 continued in the fourth quarter, resulting in total revenue up 18% over the fourth quarter of 2022, with full-y.

LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2023 financial results will be released before market open on Monday, March 4, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Monday, March 4, 2024 to discuss the financial results and recent co.

LENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024

LENSAR, Inc. (NASDAQ:LNSR ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nicholas Curtis - CEO Thomas Staab - CFO Conference Call Participants Ryan Zimmerman - BTIG Operator Good morning, and thank you for your participation. [Operator Instructions] As a reminder, this conference call is being recorded.

LENSAR, Inc. (LNSR) Q3 2023 Earnings Call Transcript

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2023 and provided an update on key operational initiatives. “We have seen continued strength in our business in the third quarter, with total revenue up 26% and U.S. procedure volume increasing 16% year-over-year. This stron.

LENSAR Reports Third Quarter 2023 Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2023 financial results will be released before market open on Thursday, November 9, 2023. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, November 9, 2023 to discuss the financial results and recent corpora.

LENSAR to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

LENSAR, Inc. (NASDAQ:LNSR ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Cameron Radinovic – Burns McClellan Nick Curtis – Chief Executive Officer Tom Staab – Chief Financial Officer Conference Call Participants Ryan Zimmerman – BTIG Operator Good morning and thank you for your participation. At this time all participants are in a listen-only mode.

LENSAR, Inc. (LNSR) Q2 2023 Earnings Call Transcript

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2023 and provided an update on key operational initiatives. “The second quarter was a strong quarter for us, which saw a substantive number of ALLY placements that we had been working on coming to fruition, resulting in a steady.

LENSAR Reports Second Quarter 2023 Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's second quarter 2023 financial results will be released before market open on Wednesday, August 9, 2023. LENSAR's management will host a conference call and webcast at 8:30 am ET on Wednesday, August 9, 2023 to discuss the financial results and recent.

News for LENSAR Inc Stock (LNSR)